PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.85%
Negative revenue growth while MCHP stands at 6.22%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-6.35%
Negative gross profit growth while MCHP is at 6.69%. Joel Greenblatt would examine cost competitiveness or demand decline.
-11.23%
Negative EBIT growth while MCHP is at 0.26%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.23%
Negative operating income growth while MCHP is at 0.26%. Joel Greenblatt would press for urgent turnaround measures.
-22.75%
Negative net income growth while MCHP stands at 1.87%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-21.74%
Negative EPS growth while MCHP is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-23.91%
Negative diluted EPS growth while MCHP is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.77%
Share reduction while MCHP is at 1.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-2.00%
Reduced diluted shares while MCHP is at 2.62%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.80%
Dividend growth under 50% of MCHP's 12.46%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-34.44%
Negative OCF growth while MCHP is at 13.60%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-40.57%
Negative FCF growth while MCHP is at 40.07%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
49.18%
10Y revenue/share CAGR under 50% of MCHP's 203.02%. Michael Burry would suspect a lasting competitive disadvantage.
130.13%
5Y revenue/share CAGR above 1.5x MCHP's 73.97%. David Dodd would look for consistent product or market expansions fueling outperformance.
30.62%
3Y revenue/share CAGR at 50-75% of MCHP's 54.99%. Martin Whitman would question if the firm lags behind competitor innovations.
101.41%
10Y OCF/share CAGR under 50% of MCHP's 646.57%. Michael Burry would worry about a persistent underperformance in cash creation.
146.61%
Below 50% of MCHP's 643.07%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
69.41%
3Y OCF/share CAGR at 75-90% of MCHP's 82.25%. Bill Ackman would press for improvements in margin or overhead to catch up.
323.19%
Below 50% of MCHP's 885.49%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
1889.18%
5Y net income/share CAGR above 1.5x MCHP's 225.39%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
68.97%
Below 50% of MCHP's 444.11%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
181.93%
Below 50% of MCHP's 585.66%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
25.48%
Below 50% of MCHP's 69.26%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.20%
Below 50% of MCHP's 42.50%. Michael Burry suspects a serious short-term disadvantage in building book value.
91.76%
Dividend/share CAGR of 91.76% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
106.54%
Dividend/share CAGR of 106.54% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
88.39%
Below 50% of MCHP's 796.27%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-1.01%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-1.95%
Inventory is declining while MCHP stands at 1.41%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-1.29%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
1.11%
Under 50% of MCHP's 2.40%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
-0.72%
Our R&D shrinks while MCHP invests at 14.30%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.93%
We cut SG&A while MCHP invests at 17.94%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.